These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37837671)

  • 1. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
    Gao G; Li J; Cao Y; Li X; Qian Y; Wang X; Li M; Qiu Y; Wu T; Wang L; Fang M
    Eur J Med Chem; 2023 Dec; 261():115858. PubMed ID: 37837671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wang WJ; Gao L; Wang S; Huang W; Meng XY; Hu H; Chen Z; Sun J; Yuan Y; Zhou Y; Diao X; Huang R; Li J; Chen XH
    J Med Chem; 2024 Jun; 67(12):10035-10056. PubMed ID: 38885173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.
    Cheng SS; Qu YQ; Wu J; Yang GJ; Liu H; Wang W; Huang Q; Chen F; Li G; Wong CY; Wong VKW; Ma DL; Leung CH
    Acta Pharm Sin B; 2022 Mar; 12(3):1390-1405. PubMed ID: 35530158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells.
    Cheng S; Yang GJ; Wang W; Ma DL; Leung CH
    Genes Dis; 2022 Nov; 9(6):1674-1688. PubMed ID: 36157485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
    J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.
    Singh U; Chashoo G; Khan SU; Mahajan P; Nargotra A; Mahajan G; Singh A; Sharma A; Mintoo MJ; Guru SK; Aruri H; Thatikonda T; Sahu P; Chibber P; Kumar V; Mir SA; Bharate SS; Madishetti S; Nandi U; Singh G; Mondhe DM; Bhushan S; Malik F; Mignani S; Vishwakarma RA; Singh PP
    J Med Chem; 2017 Dec; 60(23):9470-9489. PubMed ID: 29144137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of CDK9 in triple negative breast cancer.
    Mustafa EH; Laven-Law G; Kikhtyak Z; Nguyen V; Ali S; Pace AA; Iggo R; Kebede A; Noll B; Wang S; Winter JM; Dwyer AR; Tilley WD; Hickey TE
    Oncogene; 2024 Jan; 43(3):202-215. PubMed ID: 38001268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy.
    Sriramulu S; Thoidingjam S; Siddiqui F; Brown SL; Movsas B; Walker E; Nyati S
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
    Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
    Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
    Ren H; Bakas NA; Vamos M; Chaikuad A; Limpert AS; Wimer CD; Brun SN; Lambert LJ; Tautz L; Celeridad M; Sheffler DJ; Knapp S; Shaw RJ; Cosford NDP
    J Med Chem; 2020 Dec; 63(23):14609-14625. PubMed ID: 33200929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
    J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia.
    Zhang H; Huang J; Chen R; Cai H; Chen Y; He S; Xu J; Zhang J; Wang L
    Bioorg Med Chem; 2022 Oct; 72():116994. PubMed ID: 36087428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
    Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
    In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer.
    Nie HJ; Li BF; Sun J; Yuan Y; Zhang ZG; Hu H; Wang WJ; Chen Z; Wang S; Huang W; Diao X; Yu J; Huang R; Chen XH
    Bioorg Chem; 2024 Dec; 153():107876. PubMed ID: 39406109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.